TG Therapeutics clinical trials we track

Check company identity source

Phase 3 4 trials

Phase 2 / 3 2 trials

Phase 2 8 trials

TrialDrugs studiedStatusPrimary completion
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaNCT07680946UblituximabRecruiting2028-12-12Estimated
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)NCT07673744UblituximabRecruiting2028-07-01Estimated
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)NCT07503873Prefilled pen, UblituximabRecruiting2027-07-31Estimated
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaNCT03364231UmbralisibCompleted2022-02-15Actual
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304NCT02656303Ublituximab, UmbralisibTerminated2022-05-26Actual
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxNCT04016805Acalabrutinib Oral Capsule, Ibrutinib, Ublituximab, Umbralisib and 1 moreTerminated2022-05-22Actual
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaNCT03828448Ublituximab, UmbralisibTerminated2022-05-16Actual
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyNCT02742090UmbralisibTerminated2021-06-10Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-12-28DayUblituximabTG Therapeutics, Inc. · TGTXFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761238", "applicant_as_listed_by_fda": "TG THERAPEUTICS, INC", "brand_names": ["BRIUMVI"], "active_ingredients": ["UBLITUXIMAB-XIIY"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20221228", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Part 2: Area under the curve (AUC) From Week 0 to Week 12 [AUC(0-W12)] of Ublituximab. After: Measure: Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab.

Primary completion date changed

Before: 31 Jul 2027. After: 30 May 2027.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Area under the curve (AUC) from 0 to Week 24 of Ublituximab. After: Measure: Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Part A: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab. After: Measure: Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab.

Primary completion date changed

Before: 1 Sep 2026. After: 1 Dec 2027.

Check registry source